TSPAN1: A Novel Protein Involved in Head and Neck Squamous Cell Carcinoma Chemoresistance.

HNSCC apoptosis autophagy cancer cancer stem cells resistance

Journal

Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829

Informations de publication

Date de publication:
05 Nov 2020
Historique:
received: 08 09 2020
revised: 24 10 2020
accepted: 30 10 2020
entrez: 10 11 2020
pubmed: 11 11 2020
medline: 11 11 2020
Statut: epublish

Résumé

Sensitization of resistant cells and cancer stem cells (CSCs) represents a major challenge in cancer therapy. A proteomic study revealed tetraspanin-1 (TSPAN1) as a protein involved in acquisition of cisplatin (CDDP) resistance (Data are available via ProteomeXchange with identifier PXD020159). TSPAN1 was found to increase in CDDP-resistant cells, CSCs and biopsies from head and neck squamous cell carcinoma (HNSCC) patients. TSPAN1 depletion in parental and CDDP-resistant HNSCC cells reduced cell proliferation, induced apoptosis, decreased autophagy, sensitized to chemotherapeutic agents and inhibited several signaling cascades, with phospho-SRC inhibition being a major common target. Moreover, TSPAN1 depletion in vivo decreased the size and proliferation of parental and CDDP-resistant tumors and reduced metastatic spreading. Notably, CDDP-resistant tumors showed epithelial-mesenchymal transition (EMT) features that disappeared upon TSPAN1 inhibition, suggesting a link of TSPAN1 with EMT and metastasis. Immunohistochemical analysis of HNSCC specimens further revealed that TSPAN1 expression was correlated with phospho-SRC (pSRC), and inversely with E-cadherin, thus reinforcing TSPAN1 association with EMT. Overall, TSPAN1 emerges as a novel oncogenic protein and a promising target for HNSCC therapy.

Identifiants

DOI: 10.3390/cancers12113269 PMID: 33167355 PMC: PMC7694336
pubmed: 33167355
pii: cancers12113269
doi: 10.3390/cancers12113269
pmc: PMC7694336
pii:
doi:

Types de publication

Journal Article

Langues

eng

Subventions

Organisme : Instituto de Salud Carlos III
ID : PI15/01262
Organisme : Fundación Asociación española contra el cáncer
ID : GC16173720CARR

Références

Oncol Lett. 2017 Dec;14(6):6815-6822
pubmed: 29422958
Zentralbl Gynakol. 2002 Nov;124(11):511-24
pubmed: 12796844
Cancer Res. 2010 Oct 15;70(20):8025-35
pubmed: 20940407
Cancers (Basel). 2019 Oct 25;11(11):
pubmed: 31731442
Nucleic Acids Res. 2014 Jul;42(12):8049-61
pubmed: 24875475
Sci Rep. 2016 Apr 25;6:24704
pubmed: 27108536
Oncotarget. 2019 May 28;10(37):3435-3450
pubmed: 31191817
Protein Pept Lett. 2009;16(10):1244-8
pubmed: 19508227
Cancer Res. 2018 Jun 15;78(12):3147-3162
pubmed: 29700003
Asian Pac J Cancer Prev. 2013;14(1):557-63
pubmed: 23534794
FASEB J. 1997 May;11(6):428-42
pubmed: 9194523
FEBS Lett. 2015 Jul 8;589(15):1988-94
pubmed: 26054975
Head Neck. 2017 Nov;39(11):2329-2349
pubmed: 28815841
Oncol Rep. 2015 Aug;34(2):811-22
pubmed: 26080853
J Exp Clin Cancer Res. 2018 Dec 4;37(1):300
pubmed: 30514341
Biochem Biophys Res Commun. 2008 Dec 12;377(2):474-478
pubmed: 18851943
J Cell Mol Med. 2019 Dec;23(12):8184-8195
pubmed: 31638335
Cells. 2020 Feb 12;9(2):
pubmed: 32059478
CA Cancer J Clin. 2019 Jan;69(1):7-34
pubmed: 30620402
Sci Rep. 2017 Jul 12;7(1):5249
pubmed: 28701765
Sci Rep. 2018 Apr 13;8(1):5968
pubmed: 29654275
J Immunother Cancer. 2019 Jul 15;7(1):184
pubmed: 31307547
Cancer Lett. 2009 Mar 18;275(2):198-203
pubmed: 19017553
Semin Cancer Biol. 2020 Feb;60:166-180
pubmed: 31369817
Oncol Rep. 2015 Dec;34(6):3068-76
pubmed: 26370588
Neoplasia. 2017 Aug;19(8):649-658
pubmed: 28732212
Oncotarget. 2016 May 10;7(19):28340-55
pubmed: 27078847
Cancers (Basel). 2019 Jul 11;11(7):
pubmed: 31336714
Mol Cell Proteomics. 2019 Feb;18(2):231-244
pubmed: 30373788
Oncotarget. 2016 Sep 27;7(39):63294-63305
pubmed: 27556508
CA Cancer J Clin. 2017 Jan;67(1):31-50
pubmed: 27898173
JCI Insight. 2017 Mar 23;2(6):e90449
pubmed: 28352657
Am J Cancer Res. 2020 Apr 01;10(4):1115-1129
pubmed: 32368389
Carcinogenesis. 2019 Dec 31;40(12):1525-1534
pubmed: 31050705
Cancer Cell Int. 2014 Dec 05;14(1):135
pubmed: 25505372
Nucleic Acids Res. 2019 Jan 8;47(D1):D442-D450
pubmed: 30395289
Cancer Res. 2014 Jan 1;74(1):173-87
pubmed: 24220242
Oncogene. 1998 May 14;16(19):2447-58
pubmed: 9627111
Nature. 2017 Jan 5;541(7635):41-45
pubmed: 27974793
Nature. 2015 Apr 16;520(7547):368-72
pubmed: 25807485
Front Oncol. 2020 Jan 22;9:1522
pubmed: 32039012
Drug Resist Updat. 2018 Nov;41:1-25
pubmed: 30471641
Oncotarget. 2014 Dec 15;5(23):12083-96
pubmed: 25301729
Clin Cancer Res. 2011 Sep 15;17(18):6061-70
pubmed: 21810917
Cell Mol Life Sci. 2019 Apr;76(8):1595-1604
pubmed: 30778617
Tumori. 2008 Jul-Aug;94(4):531-8
pubmed: 18822690
Arch Dermatol Res. 2014 May;306(4):385-97
pubmed: 24196235
Tumour Biol. 2014 May;35(5):3945-51
pubmed: 24420150
Clin Cancer Res. 2010 Nov 1;16(21):5329-38
pubmed: 20837694
Cell Death Dis. 2017 Oct 26;8(10):e3141
pubmed: 29072692
Oncotarget. 2017 Mar 28;8(13):22034-22047
pubmed: 28423546
Nat Commun. 2019 Jun 28;10(1):2863
pubmed: 31253779
Cancer Cell Int. 2020 Jan 3;20:4
pubmed: 31911756
Int J Cancer. 2002 Jun 20;99(6):771-5
pubmed: 12115476
Mol Med Rep. 2018 Sep;18(3):3280-3288
pubmed: 30066932

Auteurs

Yoelsis Garcia-Mayea (Y)

Biomedical Research in Cancer Stem Cells, Vall d'Hebron Research Institute (VHIR), Autonomous University of Barcelona, Passeig Vall d'Hebron 119-129, 08035 Barcelona, Spain.
Genetic, Microbiology and Statistics Department, Faculty of Biology, University of Barcelona, Avenida Diagonal 643, 08014 Barcelona, Spain.
ORCID: 0000-0002-9395-7471

Cristina Mir (C)

Biomedical Research in Cancer Stem Cells, Vall d'Hebron Research Institute (VHIR), Autonomous University of Barcelona, Passeig Vall d'Hebron 119-129, 08035 Barcelona, Spain.

Laia Carballo (L)

Biomedical Research in Cancer Stem Cells, Vall d'Hebron Research Institute (VHIR), Autonomous University of Barcelona, Passeig Vall d'Hebron 119-129, 08035 Barcelona, Spain.

Josep Castellvi (J)

Biomedical Research in Cancer Stem Cells, Vall d'Hebron Research Institute (VHIR), Autonomous University of Barcelona, Passeig Vall d'Hebron 119-129, 08035 Barcelona, Spain.
ORCID: 0000-0001-5745-9996

Jordi Temprana-Salvador (J)

Biomedical Research in Cancer Stem Cells, Vall d'Hebron Research Institute (VHIR), Autonomous University of Barcelona, Passeig Vall d'Hebron 119-129, 08035 Barcelona, Spain.
ORCID: 0000-0001-9516-1680

Juan Lorente (J)

Otorhinolaryngology Department, Hospital Vall d'Hebron (HUVH), Passeig Vall d'Hebron 119-129, 08035 Barcelona, Spain.

Sergi Benavente (S)

Radiotherapy Unit, Vall d'Hebron Research Institute (VHIR), Autonomous University of Barcelona, Passeig Vall d'Hebron 119-129, 08035 Barcelona, Spain.

Juana M García-Pedrero (JM)

Department of Otolaryngology-Head and Neck Surgery, Central University Hospital of Asturias, University of Oviedo, ISPA, IUOPA, Spanish Biomedical Research Network Centre in Oncology (CIBERONC), Av. Roma SN, 33011 Oviedo, Spain.

Eva Allonca (E)

Department of Otolaryngology-Head and Neck Surgery, Central University Hospital of Asturias, University of Oviedo, ISPA, IUOPA, Spanish Biomedical Research Network Centre in Oncology (CIBERONC), Av. Roma SN, 33011 Oviedo, Spain.
ORCID: 0000-0002-2532-5421

Juan P Rodrigo (JP)

Department of Otolaryngology-Head and Neck Surgery, Central University Hospital of Asturias, University of Oviedo, ISPA, IUOPA, Spanish Biomedical Research Network Centre in Oncology (CIBERONC), Av. Roma SN, 33011 Oviedo, Spain.
ORCID: 0000-0003-3063-0890

Matilde E LLeonart (ME)

Biomedical Research in Cancer Stem Cells, Vall d'Hebron Research Institute (VHIR), Autonomous University of Barcelona, Passeig Vall d'Hebron 119-129, 08035 Barcelona, Spain.
Spanish Biomedical Research Network Centre in Oncology (CIBERONC), Vall d'Hebron Research Institute (VHIR), Passeig Vall d´Hebron 119-129, 08035 Barcelona, Spain.

Classifications MeSH